Q4 2015 · —
Revenue$340.88M$340.88M +3.9% vs Q4 2014+0.0% vs Q3 2015
Net Income$82.76M$82.76M +1.4% vs Q4 2014−5.9% vs Q3 2015
EPS Diluted$1.32$1.32 +1.5% vs Q4 2014−5.0% vs Q3 2015
Gross Profit$314,894,000+6.6%
Operating Incomederived$106,628,000−17.9%
Operating Cash Flowderived$119,741,000−10.8%
Free Cash Flowderived$116,374,000−3.6%
Margins · derived
Gross margin92.4%+2.3 pt vs Q4 2014
Operating margin31.3%−8.3 pt vs Q4 2014
Net margin24.3%−0.6 pt vs Q4 2014
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q4 2015 | Q4 2014 | Q4 2013 | Q4 2012 |
|---|---|---|---|---|
| Revenue | $340.88M | $328.14M | $235.77M | $183.70M |
| Net Income | $82.76M | $81.61M | $55.29M | $200.55M |
| EPS Diluted | $1.32 | $1.30 | $0.90 | $3.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR